Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13
September 12, 2022 18:30 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief...
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 09:15 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief...
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
September 01, 2022 08:30 ET
|
Celsion Corporation
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company...
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
August 15, 2022 08:00 ET
|
Celsion Corporation
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. ...
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
August 08, 2022 08:30 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
July 19, 2022 08:35 ET
|
Celsion Corporation
LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer
July 19, 2022 08:30 ET
|
Celsion Corporation
Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on...
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
June 21, 2022 08:30 ET
|
Celsion Corporation
Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit Full Enrollment Expected by Third Quarter of 2022 LAWRENCEVILLE, N.J., June 21, 2022 (GLOBE NEWSWIRE) --...
Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update
May 16, 2022 08:00 ET
|
Celsion Corporation
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., May 16, 2022 ...
Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates
May 10, 2022 08:30 ET
|
Celsion Corporation
PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies Phase II study of GEN-1 in ovarian cancer 85% enrolled with full enrollment expected in the third quarter of 2022 FDA Allows...